JP2008518591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518591A5 JP2008518591A5 JP2007538349A JP2007538349A JP2008518591A5 JP 2008518591 A5 JP2008518591 A5 JP 2008518591A5 JP 2007538349 A JP2007538349 A JP 2007538349A JP 2007538349 A JP2007538349 A JP 2007538349A JP 2008518591 A5 JP2008518591 A5 JP 2008518591A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- transcription unit
- amplicon
- derived
- tet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000013518 transcription Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 241000701161 unidentified adenovirus Species 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 20
- 108091093088 Amplicon Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 108091023040 Transcription factor Proteins 0.000 claims description 5
- 102000040945 Transcription factor Human genes 0.000 claims description 5
- 230000003584 silencer Effects 0.000 claims description 5
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 4
- 101710096438 DNA-binding protein Proteins 0.000 claims description 4
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 4
- 101710087110 ORF6 protein Proteins 0.000 claims description 4
- 101710164463 Preterminal protein Proteins 0.000 claims description 4
- 239000004098 Tetracycline Substances 0.000 claims description 4
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 claims description 4
- 230000002457 bidirectional effect Effects 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229960002180 tetracycline Drugs 0.000 claims description 4
- 229930101283 tetracycline Natural products 0.000 claims description 4
- 235000019364 tetracycline Nutrition 0.000 claims description 4
- 150000003522 tetracyclines Chemical class 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 3
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 8
- 230000002950 deficient Effects 0.000 claims 5
- 230000010076 replication Effects 0.000 claims 5
- 101150059079 EBNA1 gene Proteins 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 2
- 229960003722 doxycycline Drugs 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108010057360 Adenovirus E1 Proteins Proteins 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 108020005091 Replication Origin Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62445904P | 2004-11-02 | 2004-11-02 | |
| PCT/EP2005/011629 WO2006048215A1 (en) | 2004-11-02 | 2005-10-27 | Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518591A JP2008518591A (ja) | 2008-06-05 |
| JP2008518591A5 true JP2008518591A5 (enExample) | 2008-12-11 |
Family
ID=35705355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538349A Withdrawn JP2008518591A (ja) | 2004-11-02 | 2005-10-27 | 複製欠損アデノウイルスベクターの製造のためのアデノウイルスアンプリコンおよびプロデューサー細胞、その製造方法および用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070298498A1 (enExample) |
| EP (1) | EP1809753A1 (enExample) |
| JP (1) | JP2008518591A (enExample) |
| CA (1) | CA2585523A1 (enExample) |
| WO (1) | WO2006048215A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0719526D0 (en) | 2007-10-05 | 2007-11-14 | Isis Innovation | Compositions and methods |
| US20100285050A1 (en) | 2007-10-05 | 2010-11-11 | Isis Innovation Limited | Compositions and Methods |
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| CN102884196B (zh) * | 2010-04-01 | 2015-05-06 | 肖卫东 | 重组病毒载体的结构及其制备 |
| CN107466324B (zh) * | 2015-04-14 | 2022-01-14 | 扬森疫苗与预防公司 | 具有双向启动子的表达两种转基因的重组腺病毒 |
| US20180161455A1 (en) * | 2015-06-10 | 2018-06-14 | American Gene Technologies International, Inc. | Non-integrating viral delivery system and methods of use therof |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| CA3011529A1 (en) | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta t-cells |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS |
| KR101897499B1 (ko) | 2016-06-14 | 2018-10-04 | 배재대학교 산학협력단 | 재조합 단백질 발현 증진을 위한 유전자 절편을 포함하는 발현 벡터 |
| IL300730A (en) | 2016-07-08 | 2023-04-01 | American Gene Tech Int Inc | Pre-HIV vaccine and immunotherapy |
| JP7176756B2 (ja) | 2016-07-21 | 2022-11-22 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | パーキンソン病を処置するためのウイルスベクター |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| AU2018356538B2 (en) * | 2017-10-25 | 2023-09-28 | Nouscom Ag | Eukaryotic cell line |
| US12329793B2 (en) * | 2019-03-20 | 2025-06-17 | National University Corporation Hokkaido University | Modified adenovirus and medicine comprising same |
| KR20220144416A (ko) | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
| CN112206318B (zh) * | 2020-03-16 | 2021-08-03 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的Ad7载体疫苗 |
| US20230175011A1 (en) * | 2020-03-28 | 2023-06-08 | Greffex, Inc. | Maintaining dna fragments in eukaryotic cells, approaches and uses |
| US20230210979A1 (en) * | 2020-04-20 | 2023-07-06 | Greffex, Inc. | Engineering broadly reactive coronavirus vaccines and related designs and uses |
| MX2022015132A (es) | 2020-05-29 | 2023-03-08 | CureVac SE | Vacunas combinadas a base de acidos nucleicos. |
| CA3170741A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| US20240066114A1 (en) | 2020-08-31 | 2024-02-29 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| CN120129693A (zh) | 2022-08-01 | 2025-06-10 | 旗舰创业创新第七有限责任公司 | 免疫调节蛋白及相关方法 |
| TW202438673A (zh) | 2023-01-09 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 疫苗及相關方法 |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| WO2025024486A2 (en) | 2023-07-25 | 2025-01-30 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| CN117089577B (zh) * | 2023-08-21 | 2024-06-25 | 暨南大学 | 重组的猴腺病毒、病毒载体及构建方法 |
| WO2025128953A1 (en) | 2023-12-15 | 2025-06-19 | Flagship Pioneering Innovations Vii, Llc | Esterases and related methods |
| WO2025129034A2 (en) | 2023-12-15 | 2025-06-19 | Flagship Pioneering Innovations Vii, Llc | Esterases and related methods |
| WO2025129001A1 (en) | 2023-12-15 | 2025-06-19 | Flagship Pioneering Innovations Vii, Llc | Esterases and related methods |
| WO2025128943A1 (en) | 2023-12-15 | 2025-06-19 | Flagship Pioneering Innovations Vii, Llc | Esterases and related methods |
| US20250375499A1 (en) | 2024-01-26 | 2025-12-11 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU752284B2 (en) * | 1998-02-17 | 2002-09-12 | Genzyme Corporation | Methods for pseudoadenoviral vector production |
| JP4475561B2 (ja) * | 2001-10-11 | 2010-06-09 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃ型肝炎ウイルスワクチン |
-
2005
- 2005-10-27 JP JP2007538349A patent/JP2008518591A/ja not_active Withdrawn
- 2005-10-27 CA CA002585523A patent/CA2585523A1/en not_active Abandoned
- 2005-10-27 WO PCT/EP2005/011629 patent/WO2006048215A1/en not_active Ceased
- 2005-10-27 EP EP05801950A patent/EP1809753A1/en not_active Withdrawn
- 2005-10-27 US US11/666,783 patent/US20070298498A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518591A5 (enExample) | ||
| CN103382468B (zh) | 一种水稻基因组定点改造方法 | |
| EP0988389B1 (en) | Method for the production of non-group c adenoviral vectors | |
| Fisher et al. | Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis | |
| CA2633087C (en) | Adenoviral expression vectors | |
| WO1999053089A1 (en) | Recombinant adenovirus gene transfer vector | |
| JP2000514312A (ja) | ヘルパーウイルスとヘルパー依存性ベクターとから作製した改善されたアデノウイルスベクター | |
| US20040002060A1 (en) | Fiber shaft modifications for efficient targeting | |
| CA2779632A1 (en) | Simian adenovirus and methods of use | |
| JP2013507935A5 (enExample) | ||
| JP2009523007A5 (enExample) | ||
| CN111218477B (zh) | 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用 | |
| AU752284B2 (en) | Methods for pseudoadenoviral vector production | |
| JP2011507515A5 (enExample) | ||
| JP2008505626A5 (enExample) | ||
| Fukuda et al. | Possible mechanism of adenovirus generation from a cloned viral genome tagged with nucleotides at its ends | |
| Hartigan-O'Connor et al. | Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection | |
| JPWO2019200122A5 (enExample) | ||
| Sheppard et al. | The major late promoter and bipartite leader sequence of fowl adenovirus | |
| CN107034232B (zh) | Atg16l1基因在增强新城疫病毒的复制能力中的用途 | |
| JP2024501841A (ja) | アデノウイルス血清型３５ヘルパーベクター | |
| JP2009077737A5 (enExample) | ||
| JP2005518199A5 (enExample) | ||
| CN101363028A (zh) | 互补型高容量腺病毒载体系统及其构建的疫苗和基因治疗产品 | |
| CN116981469A (zh) | 腺病毒血清型35辅助载体 |